痛风发作期间启动降尿酸治疗效果的随机对照试验更新系统评价与荟萃分析
该系统评价与荟萃分析纳入6项随机对照试验共445例成人痛风患者,比较痛风发作期间早期启动降尿酸治疗与安慰剂或延迟启动的效果;结果显示两组在患者自评疼痛评分、痛风发作缓解时间、28至30天内复发风险及不良事件方面均无显著差异,作者认为尚无证据表明发作期间启动降尿酸治疗存在危害或获益。
要点
- 痛风发作期间早期启动降尿酸治疗与安慰剂或延迟启动相比,患者自评疼痛评分在各时间点均无差异(p≥0.42)。
- 痛风发作缓解时间无显著差异(标准化均数差0.77天;95%CI -0.26至1.79;p=0.14)。
- 后续28至30天内复发风险无显著差异(RR 1.06;95%CI 0.59至1.92;p=0.84),不良事件两组相似。
核心结论
- 作者认为,尚无证据表明痛风发作期间启动降尿酸治疗存在危害或获益。
- 作者指出,这些发现对痛风石性痛风或肾功能损害患者的适用性有限。
研究设计与样本
- 系统评价与荟萃分析,遵循PRISMA方法,检索MEDLINE、EMBASE和Cochrane Library从建库至2023年3月1日发表的英文随机对照试验。
- 纳入标准为在≥18岁成人痛风发作期间启动降尿酸治疗的随机对照试验,共纳入6项随机对照试验进行荟萃分析。
- 合并参与者共445例,其中226例随机分配至早期启动降尿酸治疗组,219例分配至安慰剂或延迟启动降尿酸治疗组。
- 使用修订版Cochrane偏倚风险工具2.0评估纳入研究质量:3项研究评为高偏倚风险,1项研究评为有一些担忧,2项研究评为低偏倚风险。
- 研究方案注册于PROSPERO,注册号CRD42023404680。
主要发现
- 在基线、第3至4天、第7至8天、第10天或第14至15天,患者自评疼痛评分均无差异(p≥0.42)。
- 痛风发作缓解时间无显著差异(标准化均数差0.77天;95%CI -0.26至1.79;p=0.14)。
- 后续28至30天内痛风复发风险无显著差异(RR 1.06;95%CI 0.59至1.92;p=0.84)。
- 不良事件在两组间相似。
- 纳入研究未报告达到目标血清尿酸的时间、降尿酸治疗的长期依从性或患者治疗满意度。
关键数值与推荐
- 共识别972项研究,其中6项随机对照试验符合纳入标准。
- 3项研究使用别嘌醇,2项研究使用非布司他,1项研究使用丙磺舒。
- 少数参与者(n=62,13.9%)患有痛风石性痛风。
- 大多数研究排除了肾功能损害患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 3项研究评为高偏倚风险,1项研究评为有一些担忧。
- 少数参与者(n=62,13.9%)患有痛风石性痛风,大多数研究排除了肾功能损害患者,作者指出这些发现对痛风石性痛风或肾功能损害患者的适用性有限。
- 纳入研究未报告达到目标血清尿酸的时间、降尿酸治疗的长期依从性或患者治疗满意度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is uncertainty about the optimal time to start urate-lowering therapy (ULT) in the setting of a gout flare. The aim was to perform a systematic review and meta-analysis of randomised controlled trials (RCTs) assessing the effects of ULT initiation during a gout flare. METHODS: This systematic review was conducted in accordance with PRISMA methodology. MEDLINE, EMBASE and The Cochrane Library were searched for studies published between database inception to 1 March 2023. RCTs published in English that examined ULT initiation during a gout flare in adults ≥18 years were included. The quality of included studies was assessed using the revised Cochrane Risk of Bias tool 2.0. Data were extracted for the following outcomes: patient-rated pain score, duration of gout flare, recurrent gout flares, time to achieve target serum urate, adherence to ULT, patient satisfaction with treatment and adverse events. Meta-analyses were performed using Review Manager v5.4. This study is registered on PROSPERO, number CRD42023404680. RESULTS: A total of 972 studies were identified and of these, six RCTs met the criteria for inclusion in the analysis. Three studies were assessed as having high risk of bias, one study as having some concerns, and two studies as having low risk of bias. In total, there were 445 pooled participants; 226 participants randomised to early initiation of ULT and 219 to placebo or delayed initiation of ULT. Allopurinol was used in three studies, febuxostat in two studies and probenecid in one study. Few participants (n = 62, 13.9 %) had tophaceous gout. Participants with renal impairment were excluded from most studies. There were no differences in patient-rated pain scores at baseline, days 3-4, days 7-8, day 10 or days 14-15 (p ≥ 0.42). Additionally, there was no significant difference in time to resolution of gout flare (standardised mean difference 0.77 days; 95 % CI -0.26 to 1.79; p = 0.14) or the risk of recurrent gout flare in the subsequent 28 to 30 days (RR 1.06; 95 % CI 0.59 to 1.92; p = 0.84). Adverse events were similar between groups. The included studies did not report time to achieve target serum urate, long-term adherence to ULT, or patient satisfaction with treatment. CONCLUSION: There appears to be no evidence for harm or for benefit to initiating ULT during a gout flare. These findings have limited applicability to patients with tophaceous gout, or those with renal impairment.
引用
- Tai V, Gow P, Stewart S, et al. An updated systematic review and meta-analysis of randomised controlled trials on the effects of urate-lowering therapy initiation during a gout flare. Semin Arthritis Rheum. 2024. PMID: 38215627. doi:10.1016/j.semarthrit.2024.152367
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。